Business context and reporting period
Filing identity: The supplied filing is IsoRay, Inc.’s unaudited Form 10-Q, not a filing under the requested company name, Perspective Therapeutics, Inc. It covers the quarter and six months ended December 31, 2013 (IsoRay fiscal Q2), compared with the periods ended December 31, 2012. IsoRay sells brachytherapy products, including Cesium-131 seeds and the GliaSite Radiation Therapy System (RTS).
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2013 | Six months ended Dec. 31, 2013 | Prior-year comparison |
|---|---|---|---|
| Product sales | $1.085 million | $2.135 million | Up 11% and 5%, respectively |
| Gross loss | $34,000 | $111,000 | Improved from $159,000 and $179,000 |
| Operating loss | $1.044 million | $2.279 million | Improved 5% quarterly; worsened 3% for six months |
| Net loss | $927,000 | $2.198 million | Prior-year losses were $1.154 million and $2.148 million |
| Net loss applicable to common shareholders | $930,000 | $2.930 million | Six-month amount includes a $726,000 Series D deemed dividend |
| Net cash used in operations | Not provided for the quarter | $1.738 million | Cash use increased 15% from $1.513 million |
Quarterly gross margin improved to approximately negative 3% from negative 16%; six-month gross margin improved to approximately negative 5% from negative 9%. Cash and cash equivalents were $4.415 million at December 31, 2013, up from $2.900 million at June 30, 2013; current assets were $5.925 million and current liabilities $847,000. The balance sheet reports no conventional borrowings; liabilities included an $829,000 asset retirement obligation and a $23,000 warrant derivative liability. Restricted cash was $181,000.
Six-month investing cash use was $16,000 and financing provided $3.269 million, principally from the August 2013 equity offering; ending cash was $4.415 million. At February 6, 2014, cash was approximately $4.31 million. The company reported 41,540,982 common shares outstanding on that date, following the January conversion of Series D preferred stock into 3,121,480 common shares.
Material changes versus prior comparable periods
- Quarterly product sales rose 11%, led by prostate sales, which increased 11%; other product sales rose 10%. Management attributed the quarterly prostate increase to higher treatment volumes at an existing facility and a new facility.
- For six months, prostate sales rose 4% and other sales rose 12%. Management said the prostate increase was concentrated in a physician whose treatment volume increased substantially, while the broader prostate market remained pressured by competing treatments.
- Cost of product sales increased 2% for six months, including $46,000 of medical-device tax and higher GliaSite RTS costs. Improved seed-production costs partly offset these increases.
- Six-month operating expenses increased 6% to $2.168 million. Higher protocol, sales staffing, and public-company costs contributed.
- Warrant fair-value changes generated non-operating income of $117,000 for the quarter and $81,000 for six months, supporting reported net income results relative to operating losses; these are valuation changes, not operating revenue.
- August 2013’s underwritten offering generated $3.279 million net proceeds. It included common and Series D preferred units and warrants; the Series D shares were converted in January 2014.
Outlook, commentary, risks, and unusual items
- Management estimated monthly required cash operating expenditures of approximately $290,000 for the six months ended December 31, 2013, 15% above the prior-year average. It believed available cash would fund operations and capital needs for at least 12 months, assuming revenue and expenses remained at current levels.
- Management planned continued protocol studies and expansion into additional brachytherapy applications, including lung and intracranial treatments, while pursuing GliaSite RTS growth and cost control. It estimated approximately $180,000 of fiscal 2014 protocol expense and less than $50,000 for anticipated GliaSite-related capital equipment.
- There is no assurance of profitability or revenue growth. Management noted that prostate-market sales had not risen enough to reach breakeven over the prior six fiscal years, and non-prostate applications remain early-stage and exposed to significant quarter-to-quarter variation and reliance on a small number of physicians.
- GliaSite customer adoption was slower than anticipated because of facility approval processes and delays in required nuclear-material license modifications. Management also cited reimbursement competition from IMRT and robotic treatments.
- The company warned that it anticipated falling below NYSE MKT minimum stockholders’ equity requirements for the quarter ending March 31, 2014 and may need to raise capital sooner if warrants are not exercised. Failure to obtain funding could lead to delisting or curtailed operations. Additional financing may be unavailable or dilutive.
- August 2013 warrants covering 5,648,738 shares, exercisable beginning March 1, 2014, carried a $0.72 exercise price, potentially reducible to $0.535 upon shareholder approval; the filing warned that the warrants could pressure the share price.
- Contingencies include a disputed know-how royalty claim, potential radioactive-material decommissioning costs, and product-liability exposure. The filing reports no off-balance-sheet arrangements.
- Management said disclosure controls were effective, but remediation of a previously identified material weakness was ongoing. The Controller was promoted to CFO effective October 1, 2013.
Important facts for investors to verify
- Confirm the issuer and period: the supplied document is IsoRay’s 2013 quarterly filing, not Perspective Therapeutics’ filing.
- Assess cash runway against the company’s operating cash burn, revenue variability, and the assumptions underlying management’s 12-month estimate.
- Verify NYSE MKT stockholders’ equity compliance, any subsequent listing notices, and the availability and terms of additional financing.
- Review the potential dilution and share-price effects of outstanding warrants, including exercise and shareholder-approval terms, and the Series D conversion’s effect on share count.
- Track whether product sales, gross margins, and adoption of non-prostate applications improve enough to reduce operating losses.
- Monitor the disputed royalty matter, asset-retirement obligations, and progress remediating the material weakness.